ライフサイエンスコーパス: donor lymphocyte infusion

1 ans for augmenting the GVL effect of delayed donor lymphocyte infusion.

2 the graft-versus-leukemia effects of delayed donor lymphocyte infusion.

3 by day 200 after cyclosporine withdrawal and donor lymphocyte infusion.

4 ended to detect and treat early relapse with donor lymphocyte infusion.

5 rdizing the graft-versus-leukaemia effect of donor lymphocyte infusion.

6 sease occurred in 5 of 14 RIC patients after donor lymphocyte infusion.

7 5 days post-transplantation and responded to donor lymphocyte infusion.

8 nd one was reinduced into continuous CR with donor lymphocyte infusion.

9 omplete donor chimerism without the need for donor lymphocyte infusion.

10 resolved after treatment with rituximab and donor lymphocyte infusion.

11 of the anti-leukemia response in vivo after donor lymphocyte infusion.

12 a complete cytogenetic remission after CD4+ donor lymphocyte infusion.

13 se (GVHD), and the toxic effects of adjuvant donor-lymphocyte infusion.

14 GVHD and seven (14%) had chronic GVHD before donor-lymphocyte infusion.

15 found to inhibit the GVL response of delayed donor lymphocyte infusions.

16 unotherapy of hematologic malignancies using donor lymphocyte infusions.

17 l transplantation (alloTCD-HSCT) followed by donor lymphocyte infusions.

18 e response with reduced immunosuppression or donor lymphocyte infusions.

19 pse either prior to or during treatment with donor lymphocyte infusions.

20 ent was accomplished only following multiple donor lymphocyte infusions.

21 s a platform for adoptive immunotherapy with donor lymphocyte infusions.

22 The sensitivity of CML to donor lymphocyte infusion after allogeneic stem cell tra

23 Similarly, the outcomes of donor lymphocyte infusion after allogenic stem cell tran

24 The majority of patients treated with donor lymphocyte infusions after relapse responded, demo

25 xperienced a complete remission after CD4(+) donor lymphocyte infusions also developed high-titer ant

26 e use of immune modulating therapies such as donor lymphocyte infusion and azacitidine.

27 ere isolated from peripheral blood after CD4 donor lymphocyte infusion and recognition of donor-deriv

28 Such treatment, as an adjunct to donor lymphocyte infusions and pharmacologic therapy, ma

29 nor selection, immunosuppression management, donor lymphocyte infusions, and pharmacological therapie

30 Donor lymphocyte infusions are associated with a signifi

31 Donor lymphocyte infusions are extremely effective for c

32 phenotype, were administered as a preemptive donor lymphocyte infusion at day 14 post-HCT.

33 Ten patients received low-dose donor lymphocyte infusions beginning 5 months after tran

34 Twelve patients received donor lymphocyte infusions +/- chemoimmunotherapy for re

35 Thirteen patients had undergone salvage donor lymphocyte infusion (DLI) (median time from DLI to

36 c cells, we assessed whether GVHD induced by donor lymphocyte infusion (DLI) affects the persistence,

37 CD8+ T cell-depleted (TCD) donor lymphocyte infusion (DLI) after TCD allogeneic hem

38 Ten dogs also received escalating doses of donor lymphocyte infusion (DLI) alone or with pentostati

39 LVL (mean, 11 L) to collect lymphocytes for donor lymphocyte infusion (DLI) and other therapies was

40 In addition, 17 patients received donor lymphocyte infusion (DLI) as interventional therap

41 geneic stem cell graft followed by postponed donor lymphocyte infusion (DLI) can experience graft-ver

42 Donor lymphocyte infusion (DLI) can restore complete rem

43 Donor lymphocyte infusion (DLI) can restore durable mole

44 In the current study, we examined whether donor lymphocyte infusion (DLI) could be used as adoptiv

45 raft-versus-leukemia-based therapies such as donor lymphocyte infusion (DLI) for chronic myelogenous

46 te for patients who achieved remission after donor lymphocyte infusion (DLI) for progression, was 65%

47 Donor lymphocyte infusion (DLI) has been used in postnat

48 Donor lymphocyte infusion (DLI) has been used to enhance

49 atched, nonmyeloablative allogeneic SCT with donor lymphocyte infusion (DLI) in patients with lymphoi

50 Donor lymphocyte infusion (DLI) is a crucial therapeutic

51 (MMB3.19) were administered 7 days following donor lymphocyte infusion (DLI) or RLI on day 35.

52 geneic bone marrow transplantation (BMT) and donor lymphocyte infusion (DLI) provide valuable treatme

53 Donor lymphocyte infusion (DLI) re-establishes failing g

54 Donor lymphocyte infusion (DLI) reliably induces durable

55 Prophylactic donor lymphocyte infusion (DLI) strategies are recommend

56 Delayed administration of donor lymphocyte infusion (DLI) to established mixed chi

57 Donor lymphocyte infusion (DLI) was administered in 26 e

58 Fifty-three of 446 patients received donor lymphocyte infusion (DLI) with a median CD3 dose o

59 Donor lymphocyte infusion (DLI), a standard relapse trea

60 ulations play a critical role in response to donor lymphocyte infusion (DLI), an established and pote

61 lant may achieve durable remission following donor lymphocyte infusion (DLI), showing the potency of

62 Donor lymphocyte infusion (DLI), whereby donor mononucle

63 their phenotype, and their role in governing donor lymphocyte infusion (DLI)-mediated alloresponses.

64 ion; 2 of these patients received concurrent donor lymphocyte infusion (DLI).

65 ute hepatitislike presentation of GVHD after donor lymphocyte infusion (DLI).

66 ow grafts, exceeding the survival benefit of donor lymphocyte infusion (DLI).

67 verted to full donor chimerism by the use of donor lymphocyte infusion (DLI; P = .03).

68 performed of the response to treatment with donor lymphocyte infusions (DLI) and the survival in 66

69 Donor lymphocyte infusions (DLI) can induce remissions i

70 The clinical efficacy of donor lymphocyte infusions (DLI) in patients with relaps

71 Donor lymphocyte infusions (DLI) provide effective thera

72 disease (GVHD) by delayed administration of donor lymphocyte infusions (DLI) to established mixed ch

73 We evaluated the ability of donor lymphocyte infusions (DLI) to mediate GVL effects

74 cal immunosuppression on the in vivo fate of donor lymphocyte infusions (DLI)-derived T cells, their

75 The use of donor lymphocytes infusion (DLI) continues to treat rela

76 The effectiveness of donor-lymphocyte infusion (DLI) for treatment of relapse

77 chimeric antigen receptor (CAR) product (CAR-donor lymphocyte infusion [DLI]) for adult patients with

78 lymphocytes from the original marrow donor (donor lymphocyte infusions [DLI]) is remarkably effectiv

79 Donor lymphocyte infusions (DLIs) 35 days after bone mar

80 tem cell transplantation (HSCT) and received donor lymphocyte infusions (DLIs) after transplantation.

81 after reduced-intensity allografts and while donor lymphocyte infusions (DLIs) can be effective salva

82 of this strategy remains of interest because donor lymphocyte infusions (DLIs) can induce a potent gr

83 Donor lymphocyte infusions (DLIs) can produce lasting re

84 nancies often are treated with unmanipulated donor lymphocyte infusions (DLIs) from the transplant do

85 We describe the toxicity and efficacy of donor lymphocyte infusions (DLIs) given to 81 patients (

86 Standard salvage chemotherapy and donor lymphocyte infusions (DLIs) have little curative p

87 Donor lymphocyte infusions (DLIs) induce effective graft

88 Donor lymphocyte infusions (DLIs) induce potent graft ve

89 y the mechanisms governing the activation of donor lymphocyte infusions (DLIs) manifesting as lymphoh

90 We aimed to assess the impact of donor lymphocyte infusions (DLIs) on relapse incidence w

91 The ability of donor lymphocyte infusions (DLIs) to induce complete res

92 Donor lymphocyte infusions (DLIs) were given to 14 patie

93 Dendritic cell vaccines and donor lymphocyte infusions (DLIs) were incorporated into

94 ent of animals with NST, posttransplantation donor lymphocyte infusions (DLIs), and a vaccine, compri

95 y that persisted after alloHSCT and standard donor lymphocyte infusions (DLIs).

96 ronic myeloid leukemia patients who received donor lymphocyte infusions following transplant relapse.

97 BackgroundResponses to conventional donor lymphocyte infusion for postallogeneic hematopoiet

98 ntation is being explored through the use of donor lymphocyte infusions for patients who have relapse

99 Donor lymphocyte infusions for treatment of relapse afte

100 16 (33%) patients received donor-lymphocyte infusion from 3 months after transplant

101 Since donor lymphocyte infusions have clinical activity in JMM

102 n proven by the demonstration of response to donor lymphocyte infusion in patients relapsing after al

103 The ability to induce remissions with donor lymphocyte infusion in patients with CLL, Richter'

104 evidence for its presence is the efficacy of donor lymphocyte infusions in generating anti-tumor resp

105 Donor lymphocyte infusion induced GVHD in nine of 23 pat

106 Unfortunately, donor lymphocyte infusion induced severe cortisone-resis

107 Intervention-free survival (IFS) included donor lymphocyte infusion, infusion of donor CD34-select

108 hematopoietic stem cell transplantation and donor lymphocyte infusion is essential for acute graft v

109 Prophylactic or preemptive donor lymphocyte infusion may be useful, but requires co

110 Donor lymphocyte infusions may also be used both prophyl

111 osuppression, antiviral therapy, unprocessed donor lymphocyte infusion, mobilized peripheral blood pr

112 meliorated the severity of GVHD in a delayed donor lymphocyte infusion model.

113 d graft-versus-leukemia responses in delayed donor lymphocyte infusion models.

114 nt research is focusing on methods of making donor lymphocyte infusions more effective in the nonchro

115 ant cells or mixed chimerism could receive a donor lymphocyte infusion of 0.5 to 2 x 10(8) mononuclea

116 by cytoreductive therapy, followed either by donor lymphocyte infusion or second HSCT for consolidati

117 eduction of immune suppression plus or minus donor lymphocyte infusion or stem cell boost, which stab

118 d consolidative cellular therapies including donor lymphocyte infusions or a second allogeneic transp

119 (second HSCT, unconditioned stem cell boost, donor lymphocyte infusion, or splenectomy).

120 Adjusting the timing and dose of donor lymphocyte infusion reduces the risk of graft-vers

121 patient peripheral blood at the time of the donor lymphocyte infusion response.

122 Subsequent donor lymphocyte infusion resulted in a significant chan

123 ited progress, stem cell transplantation and donor lymphocyte infusions show that modulation of the i

124 eated for relapsed MM after alloTCD-HSCT and donor lymphocyte infusions, supporting the development o

125 All types of cell-based therapies, from donor lymphocyte infusion to dendritic cell vaccines, an

126 chimerism in the presence of GVHD after CD4 donor lymphocyte infusion was observed in a patient, HLA

127 Donor lymphocyte infusions were given as part of the RIS

128 Escalating doses of donor lymphocyte infusions were given from 6 months afte

129 Donor lymphocyte infusions were given from 6 months for

130 Donor lymphocyte infusions were given to 18 patients eit

131 nd can preclude the administration of graded donor lymphocyte infusions, which may optimize the thera